No Detail Found!

Risk of Autoimmune Thyroid Dysfunction in Multiple Sclerosis Patients Treated with Alemtuzumab: A Systematic Review

Author(s)
Nesmah Rashed College of Pharma, Alfaisal University, Riyadh, 11533, Saudi Arabia
Tasneem Rashed Adam Department of Dental Health, King Saud University, Riyadh, 11451, Saudi Arabia
Noor Hamed College of Medicine, Alfaisal University, Riyadh, 11533, Saudi Arabia
Ahmed Hamed Faculty of Radiology, Aberdeen Royal Infirmary, Aberdeen, GBR, Scotland
Zahra Mohammed Ali Alhaji Department of Home Health Care, Omran General Hospital, Imam Abdurahman Al Faisal University, Dammam 34212, Saudi Arabia
Elyas Ahmed Alharbi Department of Medicine and Surgery, Vision Colleges, Riyadh, 12211, Saudi Arabia
Turki Mohammed Ali Alobaid Department of Medicine and Surgery, Vision Colleges, Riyadh, 12211, Saudi Arabia
Nada Adel Sagr General Practitioner, Umm Al Qura University, Makkah, 21442, Saudi Arabia
Mona Abdelbaky Department of NICU, Prince Sultan Military Medical City, Riyadh, 11159, Saudi Arabia
Amin Ahmed Mohamed Ahmed MOH-Aseer Cluster-Tabalah General Hospital-Medicine Dialysis, Saudi Arabia
Abstract
Objectives: This systematic review consolidates current evidence to delineate the spectrum of alemtuzumabinduced thyroid autoimmunity in patients with MS. Methods: PubMed, Embase, Web of Science, Cochrane Library and ClinicalTrials.gov were searched up to June 2025 for studies reporting thyroid outcomes following alemtuzumab in MS. Eligible designs included randomized trials and observational cohorts. Data were extracted on incidence, subtype distribution, time to onset and management. Study quality was assessed using the Newcastle-Ottawa Scale and Cochrane/ROBINS-I tools. Results: Out of 2,397 records, 11 studies met inclusion criteria, encompassing approximately 1,626 participants. AITD occurred in about one-third of treated individuals. Graves' disease was the predominant phenotype (33-65% of cases), followed by Hashimoto's thyroiditis and TRAb-positive hypothyroidism. Onset typically occurred 18-30 months after the first infusion, peaking around year 3. Fluctuating courses between hyper- and hypothyroidism were reported in up to 15% of cases. Most events were mild or moderate and controlled with antithyroid drugs or levothyroxine; radioiodine or thyroidectomy were rarely required. Conclusion Autoimmune thyroid dysfunction is a frequent and distinctive complication of alemtuzumab in MS. The majority of cases are manageable, but the unpredictable course warrants regular thyroid-function testing every three months for at least four years after treatment and continued long-term surveillance.
Publication Details
Page(s) 67-73
DOI DOI not available
Published Journal: Journal of Pioneering Medical Sciences, Volume: 14, Issue: 12, Year: 2025

Request the full text from PASTIC

Keywords
2Researcher, 4, 1Pharmacist, 5, 8, 6, 7, 3, Author Designation, 10Physician, 9Consultant
References
Dobson R.,G. Giovannoni. R. . .Multiple sclerosis - A review. European Journal of Neurology, 26(2019) : 27-40.
Noto S.,Miyake S. .2020 .Gut dysbiosis and multiple sclerosis. ” Clinical Immunology, 235 : .
Brownlee W.J. .2017 .Diagnosis of multiple sclerosis: Progress and challenges. The Lancet, 6736(16) : 30959-1346.
Ford H. “ . .Clinical presentation and diagnosis of multiple sclerosis. ” Clinical Medicine, 20(2020) : 0292-383.
Ruck T. . .Alemtuzumab in multiple sclerosis: Mechanism of action and beyond. International Journal of Molecular Sciences, 16(2015) : 16414-16439.
Costelloe L. . .Secondary autoimmune diseases following alemtuzumab therapy for multiple sclerosis. ” Expert Review of Neurotherapeutics, 12(2012) : 335-341.
Ruck T. . .Alemtuzumab-induced immune phenotype and repertoire changes: Implications for secondary autoimmunity. ” Brain, 145(2022) : 1711-1725.
Scappaticcio L. . .Alemtuzumab-induced thyroid events in multiple sclerosis: A systematic review and meta-analysis. ” Journal of Endocrinological Investigation, 43(2020) : 219-229.
Yang J. .2024 .Risk of secondary autoimmune diseases with alemtuzumab treatment for multiple sclerosis: A systematic review and meta-analysis. ” Frontiers in Immunology, 15 : .
Moher D. .2010 .Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. International Journal of Surgery, 02(2010) : 336-341.
Carroll . .“2017 McDonald MS diagnostic criteria: Evidencebased revisions. ” Multiple Sclerosis Journal, 24(2018) : 92-95.
Wells G.A. .2000 .The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomized Studies in MetaAnalyses. , : .
Higgins J.P.T. .2011 .The Cochrane Collaboration's tool for assessing risk of bias in randomized trials. ” BMJ, 343 : .
Milo R.,Alemtuzumab R. . .. , : .
Havrdova E. . .Alemtuzumab in the treatment of multiple sclerosis: Key clinical trial results and considerations for use. ” Therapeutic Advances in Neurological Disorders, 8(2015) : 31-45.
Daniels G.H. . .Alemtuzumab-related thyroid dysfunction in a phase 2 trial of patients with relapsingremitting multiple sclerosis. The Journal of Clinical Endocrinology and Metabolism, 99(2014) : 2201-89.
Manso J. . .Alemtuzumab-induced autoimmune thyroid events in patients with relapsing-remitting multiple sclerosis. ” Clinical Endocrinology, 97(2022) : 331-338.
Dayan C.M. .2023 .Endocrine and multiple sclerosis outcomes in patients with autoimmune thyroid events in the alemtuzumab CARE-MS studies. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 9(1) : .
Decallonne B. . .Thyroid disorders in alemtuzumabtreated multiple sclerosis patients. ” Acta Neurologica Belgica, 118(2018) : 153-159.
Conway J.V. .2022 .Graves' disease following commencement of alemtuzumab therapy. ” Journal of Clinical and Translational Endocrinology: Case Reports, 25 : .
Carrion Santiago,A.M. Santiago,Agosto-Vargas. Y. . .An unusual etiology of Graves' disease:. Alemtuzumab.” Journal of the Endocrine Society, 5(2021) : A921-A922.
Pariani N. . .Alemtuzumab-induced thyroid dysfunction exhibits distinctive clinical and immunological features. The Journal of Clinical Endocrinology and Metabolism, 103(2018) : 00359-3018.
Rapier B. .2020 .Progression of Graves' disease to Hashimoto's thyroiditis following alemtuzumab therapy. ” Journal of the Endocrine Society, 518(suppl) : .
Gong M.S. .1962 .Graves' disease secondary to alemtuzumab use. ” Journal of the Endocrine Society, 7(suppl) : .
Rodríguez de Castro B. . .Alemtuzumab for relapsing multiple sclerosis in clinical practice. International Journal of Risk and Safety in Medicine, 31(2020) : 259-265.
Willis M. . .Alemtuzumab for multiple sclerosis: Longterm follow-up in a multi-centre cohort. ” Multiple Sclerosis Journal, 22(2016) : 1215-1223.
Bose G. .2021 .A real-world single-centre analysis of alemtuzumab and cladribine for multiple sclerosis. ” Multiple Sclerosis and Related Disorders, 52 : .
Sovetkina A. . .Development of autoimmune thyroid disease in multiple sclerosis patient's post-alemtuzumab. The Journal of Clinical Endocrinology and Metabolism, 105(2020) : e3392-e3399.
Yap S.M. .2020 .Alemtuzumab-related thyroid disease in people with multiple sclerosis. ” Multiple Sclerosis Journal - Experimental, Translational and Clinical, 6(2) : .
Coles A.J. .1999 .Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis.” The Lancet. , 354(9191) : 1691-1695.
Eichau S. .2023 .Results of treatment with alemtuzumab in a Spanish cohort. , 14 : .
Fox E. .2011 .A single-arm, open-label study of alemtuzumab. European Journal of Neurology, 03507(2012) : 1331-311.
Rotondi M. .2017 .Autoimmune thyroid diseases in patients treated with alemtuzumab. ” Frontiers in Endocrinology, 8 : .
Kazakou P. . .Thyroid autoimmunity following alemtuzumab treatment. ” Clinical and Experimental Medicine, 23(2023) : 2885-2894.
Hansen J.F. .2024 .Alemtuzumab-induced thyroid disease. ” Multiple Sclerosis and Related Disorders, 91 : .
Ragavan S. .2022 .Alemtuzumab-induced autoimmune thyroid dysfunction. ” Cureus, 14(3) : .
Sandgren S. .2023 .The role of autoimmune antibodies to predict secondary autoimmunity. , 14 : .
Muller I. .2018 .Longitudinal characterization of autoantibodies to the thyrotropin receptor. ” Thyroid, 28(12) : 1682-1693.
Tran B. .2024 .. Fluctuating Graves' disease.” Journal of the Endocrine Society, 8(suppl) : 1960.
0

Citations

0

Downloads

10

Views